Impilo believes in transparency. We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Accordingly, we present information about our operations and our investments in order to increase transparency. 

If you would like to receive a notification via e-mail when we publish a news update please submit your e-mail adress below. 


Impilo has closed its second investment pool

Impilo AB, the Nordic investment company focused on healthcare investments, has secured new commitments from new and existing...

Mallax acquires Sana Pharma Medical and creates a new Nordic

Mallax Pharmaceuticals AB (”Mallax”) has acquired Sana Pharma Medical AS (”SPM” or the “Company”) and creates a new Nordic...

Impilo’s divestment of NutraQ to Orkla completed

On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading...

Aeglea BioTherapeutics and Immedica Announce Commercialization

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLAeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzymeE)
Microscope is used for conducting planned, research experiments, educational demonstrations in medical and health institutions, lab.

Impilo Acquires Scantox A/S, a Leading Danish Pre-Clinical Contract Research

Today, the Danish pre-clinical contract research organization (“CRO”), Scantox A/S (“Scantox” or the “Company”) announced that it has been...

Immedica and WinHealth enter agreement giving Winhealth rights to

Immedica Pharma AB and Hongkong WinHealth Pharma Group CO., Ltd, today announce that they have entered an agreement under which...

Impilo and Anders Larnholt form a partnership to create a new pan‐

Impilo is pleased to have partnered with Anders Larnholt, an experienced pharma and healthcare executive, to create a new platform; Mallax...

Immedica acquires the rights for Ravicti® and Buphenyl® for Japan

Immedica today announces that it has acquired the rights for the products Buphenyl® (sodium phenylbutyrate) and Ravicti® (glycerol...

PharmaMar signs an agreement with Immedica

PharmaMar signs an agreement with Immedica Pharma to market lurbinectedin in Eastern Europe, the UK, Ireland, the Nordic countries and...


We know that our operations arouse curiosity and we understand the importance of maintaining an open relationship with the outside world. Here you will find press information, news and media material.

Redefining know-how

Impilo is zulu and xhosa meaning life, health or simply the meaning of a healthy life. We chose this name to highlight our sector-focus and our ambition to provide know-how and new perspectives to Nordic healthcare companies.